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Abstract The improvement of the rutin photostability
and its prolonged in vitro antioxidant activity were studied
by means of its association with nanostructured aqueous
dispersions. Rutin-loaded nanocapsules and rutin-loaded
nanoemulsion showed mean particle size of 124.30 ± 2.06
and 124.17 ± 1.79, respectively, polydispersity index
below 0.20, negative zeta potential, and encapsulation
efﬁciency close to 100%. The in vitro antioxidant activity
was evaluated by the formation of free radical  OH after the
exposure of hydrogen peroxide to a UV irradiation system.
Rutin-loaded nanostructures showed lower rutin decay
rates [(6.1 ± 0.6) 10
-3 and (5.1 ± 0.4) 10
-3 for nano-
capsules and nanoemulsion, respectively] compared to the
ethanolic solution [(35.0 ± 3.7) 10
-3 min
-1] and exposed
solution [(40.1 ± 1.7) 10
-3 min
-1] as well as compared to
exposed nanostructured dispersions [(19.5 ± 0.5) 10
-3 and
(26.6 ± 2.6) 10
-3, for nanocapsules and nanoemulsion,
respectively]. The presence of the polymeric layer in
nanocapsules was fundamental to obtain a prolonged
antioxidant activity, even if the mathematical modeling of
the in vitro release proﬁles showed high adsorption of rutin
to the particle/droplet surface for both formulations. Rutin-
loaded nanostructures represent alternatives to the devel-
opment of innovative nanomedicines.
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Introduction
Currently, there is a growing interest in the study of anti-
oxidants [1, 2]. Recent discoveries have pointed out the
effects of free radicals in the body, which are involved in
energy production, phagocytosis, and regulation of cell
growth among others [3]. Oxidative stress is a condition that
occurs in a system when the generation of reactive oxygen
species exceeds the capacity of neutralization and disposal
system. The instability may result from a lack of antioxidant
capacity caused by disturbances in the production, distri-
bution, or by an abundance of reactive oxygen species from
endogenous sources or stressful environmental conditions.
Oxidative stress has been implicated in a growing list of
diseases such as cardiovascular and neurodegenerative
diseases, cancer, arthritis, hemorrhagic shock, cataracts, as
well as in aging processes [3–5].
Among the various classes of antioxidants, naturally
occurring phenolic compounds have received much atten-
tion in recent years due to their inhibition of lipid peroxi-
dation and lipoxygenase [4]. The antioxidant activity of
phenolic compounds is mainly related to their reducing
properties and chemical structure [6]. These characteristics
play an important role in the neutralization or sequestration
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both in the initiation step and in the propagation of oxida-
tion [6]. The intermediate species formed by the action of
antioxidant phenolic compounds are relatively stable due to
the resonance of the aromatic ring in their structure [7].
Natural ﬂavonoids are phenolic compounds known for
their signiﬁcant scavenging properties on oxygen radicals
both in vivo and in vitro [8, 9]. Many studies have showed
the importance of their antiradical activity [10–13].
Moreover, their actions in humans have been subject of
extensive research, and natural ﬂavonoids have been
described to possess several biological activities such as
antioxidant, anti-inﬂammatory, antitumor, and antiviral
properties [14].
Rutin (quercetin-3-O-rutinoside), the glycoside of
quercetin, is abundantly found and distributed in plants
such as in buckwheat seed, fruits, and fruit rinds, especially
citrus fruits (orange, grapefruit, lemon). It presents
important properties in human health like its signiﬁcant
scavenging properties on oxidizing species such as
hydroxyl radical, superoxide radical, and peroxyl radical
[15], as shown by many in vitro and in vivo experiments
[16–18]. Furthermore, rutin has several pharmacological
activities including anti-allergic, anti-inﬂammatory, and
vasoactive properties [15, 19, 20]. Rutin offers an advan-
tage over other ﬂavonoids, which in some occasions
behave as pro-oxidant agents and catalyze oxygen pro-
duction [15]. Therefore, it is considered a non-toxic mol-
ecule and not oxidized. On the other hand, the main
disadvantage of the molecule is its poor solubility in
aqueous media, explaining its poor oral or topical bio-
availability [19] and being a drawback to its conversion in
adequate dosage forms.
In the last decade, an alternative drug delivery approach
was developed to overcome the poor water solubility of
rutin by reducing its particle size [19]. A decrease in the
drug particle size leads to an increase in the saturation
solubility, to an enlarged surface area and to a higher
dissolution velocity [21]. Formulating rutin as drug nano-
crystals has signiﬁcant importance to improve its physi-
cochemical properties, especially its oral bioavailability.
Some studies have shown techniques for lyophilization and
spray drying nanocrystals of rutin in order to ensure their
redispersibility as separate and non-aggregated particles.
This characteristic is a critical point to improve the dis-
solution behavior of drugs, especially from a tablet dosage
form [19, 20].
On the other hand, polymeric nanoparticles have been
designed to encapsulate lipophilic drugs not only to
improve their physicochemical properties but also to target
organs or tissues, to avoid drug degradation, to improve
drug efﬁcacy, and to circumvent drug toxicity [22].
Nanocapsules are polymeric nanoparticles composed of an
oily core surrounded by a polymeric wall stabilized by
surfactants at the particle/water interface [23]. The poten-
tial use of nanocapsules includes the protection of drugs
against inactivation in the gastrointestinal tract [21],
delivery of poorly water-soluble compounds [24, 25], and
protection of sensitive materials to chemical degradation
induced by UV light [26–28]. As the polymeric nanopar-
ticles, nanoemulsions have been also investigated as drug
delivery systems in the last years [29–32]. These colloidal
systems are composed of oily nanodroplets stabilized by
surfactants in an aqueous medium.
All these considerations into account, the main objective
of our study was to develop aqueous rutin delivery systems
and to evaluate the inﬂuence of the association of rutin to
different nanostructures (nanocapsules and nanoemulsions)
on its in vitro antioxidant activity and UV photostability.
Nanocapsules and nanoemulsions were compared to
establish the importance of the polymeric layer around the
nanodroplets by means of a systematic physicochemical
characterization of both formulations. The development of
such formulations aimed to obtain aqueous systems con-
taining rutin, as an intermediate or ﬁnal pharmaceutical
product. To the best of our knowledge, no report on the
association of rutin to polymeric nanocapsules is currently
available in the scientiﬁc literature. The administration of
ﬂavonoids by means of nanovectors may be useful for the
development of advanced delivery systems for these
powerful compounds, in view of their adoption in primary
and secondary disease prevention, either for oral or par-
enteral administration [33].
Materials and Methods
Materials
Rutin, poly-(e-caprolactone) (PCL), and sorbitan monos-
tearate (Span 60
) were acquired from Sigma–Aldrich
(Sa ˜o Paulo, Brazil). Polysorbate 80 (Tween 80
) was
supplied by Henrifarma (Sa ˜o Paulo, Brazil). Grape seed oil
was obtained from Dellaware (Porto Alegre, Brazil). All
other chemicals and solvents presented pharmaceutical or
HPLC grade and were used as received.
Preparation of Nanoparticles
Rutin-loaded nanocapsule suspensions (R-NC) and nano-
emulsions (R-NE) were prepared in triplicate (n = 3) by
the interfacial deposition of preformed polymer method
and spontaneous emulsiﬁcation, respectively [34, 35]. For
the preparation of nanocapsules, an organic solution con-
taining the grape seed oil (3.3 ml), sorbitan monostearate
(0.776 g), the polymer (1.0 g), and acetone (147 ml) was
1604 Nanoscale Res Lett (2010) 5:1603–1610
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After 1 h, an ethanolic solution containing the rutin
(120 ml) was added to this organic phase maintaining the
agitation for a further 10 min. Then, the organic phase was
injected into an aqueous phase (534 ml) containing Tween
80
 (0.776 g). Acetone was removed and the aqueous
phase concentrated to 100 ml by evaporation at 40C under
reduced pressure reaching a ﬁnal concentration of
0.25 mg ml
-1 of rutin. All formulations were stored at
room temperature and protected from light (amber glass
ﬂasks). Nanoemulsions were prepared using the same
experimental conditions, but omitting the presence of the
polymer in the organic phase. In addition, in order to
evaluate the inﬂuence of rutin in the physicochemical
characteristics of such nanostructures, blank formulations
(placebo) were prepared similarly, but omitting the pres-
ence of rutin. These formulations were called B-NC and
B-NE, for blank nanocapsules and blank nanoemulsions,
respectively. Table 1 summarizes the abbreviation pre-
sented in Tables and Figures.
Characterization of Nanoparticles
Rutin Content
Rutin was assayed by liquid chromatography (LC). The
chromatographic system consisted of a Gemini RP-18
column (150 9 4.60 mm, 5 lm, Phenomenex, Torrance,
USA) and a Shimadzu instrument (LC-10AVP Pump, UV–
VIS SPD-10AVP Module, Class-VP Software, Shimadzu,
Tokyo, Japan). The mobile phase consisted of methanol/
water (50:50% v/v) acidiﬁed with phosphoric acid
(apparent pH 4.0) pumped at a ﬂow rate of 1.0 ml min
-1.
The volume injected was 20 ll, and rutin was detected at
352 nm. Rutin content (mg ml
-1) was determined (n = 3)
after its extraction with methanol from nanocapsules or
nanoemulsions (1.6 ml of the formulation to 10 ml of
methanol) and dilution with the mobile phase to a con-
centration of 20 lgm l
-1. Validation of the LC assay
demonstrated that this method was linear (y = 30,3229
– 6,233.7, r = 0.9999, n = 5) in the range of 5–30
lgm l
-1, precise (RSD: 1.86% for repeatability and 0.70%
for intermediate precision) and accurate (RSD: 1.70%).
The speciﬁcity was tested in presence of the nanoparticle
adjuvants and demonstrated that they did not alter the rutin
assay [36].
Encapsulation Efﬁciency
Free rutin was determined in the ultraﬁltrate after separa-
tion of the nanoparticles by ultraﬁltration/centrifugation
technique (Microcon 10,000 MW, Millipore). Encapsula-
tion efﬁciency (%) was calculated by the difference
between the total and free rutin concentrations determined
in the nanoparticles (drug content) and in the ultraﬁltrate,
respectively, using the LC method previously described.
pH Measurements
The pH values of formulations were determined by
immersion of the electrode directly in the dispersions using
a calibrated potentiometer (MPA-210 Model, MS-Tecno-
pon, Sa ˜o Paulo, Brazil), at room temperature.
Particle Size Analysis, Polydispersity Indices, and Zeta
Potential
Particle sizes and polydispersity indices (n = 3) were
measured by photon correlation spectroscopy after ade-
quate dilution of an aliquot of the suspension in reverse
osmosis water (Brookhaven Instruments Corporation,
USA). The zeta potentials were determined after dilution of
the samples in 10 mM NaCl aqueous solution (Brookhaven
Instruments Corporation, Holtsville, USA).
Table 1 List of nomenclatures
presented in tables and ﬁgures
Abbreviation Meaning
B-NC Blank nanocapsules (nanocapsules prepared without drug)
R-NC Rutin-loaded nanocapsules
B-NE Blank nanoemulsion (nanoemulsion prepared without drug)
R-NE Rutin-loaded nanoemulsion
R-SE Rutin ethanolic solution
k Release rate constant according (monoexponential kinetic)
k1 Release rate constant of the burst phase (biexponential kinetic)
k2 Release rate constant of the sustained phase (biexponential kinetic)
a Initial concentration of rutin at the burst phase (biexponential kinetic)
b Initial concentration of rutin at the sustained phase (biexponential kinetic)
r Regression coefﬁcient
MSC Model selection criteria
Nanoscale Res Lett (2010) 5:1603–1610 1605
123Morphological Analyses
Morphological analyses were conducted at Centro de Mi-
croscopia (UFRGS, Brazil) by transmission electron
microscopy (TEM; Jeol, JEM 1200 Exll, Japan) operating
at 80 kV. Diluted suspensions and nanoemulsions were
deposited on specimen grid (Formvar-Carbon support
ﬁlms, Electron Microscopy Sciences), negatively stained
with uranyl acetate solution (2% w/v) [37] and observed at
different magniﬁcations.
Antioxidant Activity and Photostability Study
The system for the irradiation of the samples was devel-
oped by Carvalho et al. [38] and consisted of a 400 W
high-pressure mercury lamp (Silvania) as UV radiation
source, a cooling system based on air and water circulation,
a thermo-regulator for the temperature control, a holder for
12 quartz tubes, and an aluminum-based block. In quartz
tubes, 10 ml of each sample (R-NC, R-NE and a rutin
ethanolic solution—R-ES) was placed and exposed to UV
radiation for 30 min (n = 3). Every 5 min, samples were
taken from the tubes and analyzed by LC to determine the
content of rutin. In order to determine the antioxidant
activity, 40 llH 2O2 was added to the sample before
starting the irradiation process. The amount of H2O2 was
added in excess, since the concentration of H2O2 is 10
times the concentration of the sample and the lamp has a
limiting quantum yield for the photolysis of H2O2. The
artiﬁcial generation of the hydroxyl radical was carried out
by the decomposition of H2O2 in the presence of UV
radiation (Eq. 1):
H2O2 þ hv ! 2   OH ð1Þ
The kinetic constant for the reaction of rutin with the  OH
radical was determined by subtracting the contribution of
direct photolysis of rutin from the  OH radical reaction
kinetic constant, according to the following equation
(Eq. 2):
kOHþhv   khv ¼ kOH ð2Þ
where kOH ? hv represents the kinetic constant determined
by the rutin decay after UV photolysis in the presence of
H2O2, khv represents the kinetic constant determined by the
direct photolysis of rutin in absence of H2O2, and kOH
represents the liquid free radical reaction kinetic constant
of the  OH radical with the antioxidant.
In Vitro Rutin Release Assay
In vitro drug release proﬁles from rutin-loaded nanostruc-
tures were evaluated (n = 3) by the dialysis bag method,
using water/ethanol (65:35 v/v) as medium, at 37C[ 39].
The dialysis bag (Spectra Por 7, 10 Kd, Biosystems) con-
taining 1 ml of the sample (0.25 mg ml
-1) was put into a
glass test-tube containing 200 ml of dissolution medium.
This system was maintained under constant moderate
stirring during all the time. The withdrawal of 2 ml of the
external medium from the system was done at predeter-
mined time interval, replaced by an equal volume of fresh
medium, and ﬁltered through a 0.45-lm membrane. Rutin
was assayed in the samples by LC according to the method
previously described. However, the injection sample vol-
ume was increased to 100 ll to allow the assay of rutin at
lower concentrations. This LC method was validated
according to the following characteristics: linearity
(y = 167,8069?1,170.3, n = 3, r = 0.9997), concen-
tration range (0.1–2.0 mg ml
-1), and precision (RSD:
0.90%).
In order to obtain a better understanding of the inﬂuence
of the type of nanoparticle structure on the rutin release
behavior, the mathematical modeling (MicroMath
 Sci-
entist
 for Windows) was used to analyze the drug release
proﬁles. Monoexponential (C = C0e
-kt) and biexponential
(C = ae
-k
1
t ? be
-k
2
t) models were used to evaluate the
rutin release proﬁles. The release rate constants are k, k1,
and k2 and the initial concentration of rutin are C0, a, and b.
The selection of the model that best ﬁt the release proﬁles
was based on the best correlation coefﬁcient, the best
model selection criteria (MSC), both provided by the
software and the best graphic adjustment. The meaning of
all these abbreviations is presented in Table 1.
Statistical Analysis
Formulations were prepared and analyzed in triplicate.
Results are expressed as mean ± SD (standard deviation).
Two-way analysis of variance (ANOVA) was employed in
the comparison of the experimental data. Post hoc multiple
comparisons were done by Tukey’s test for signiﬁcance at
p–values B 0.05. All analyses were run using the Sigm-
aStat Statistical Program (Version 3.0, Jandel Scientiﬁc,
USA).
Results and Discussion
Preparation and Physicochemical Characterization
of Aqueous Nanostructured Systems
All formulations appeared macroscopically homogeneous
and their aspects were similar to a milky bluish opalescent
ﬂuid (Tyndall effect). The physicochemical characteristics
of the formulations are presented in Tables 2 and 3. As can
be seen, the formulations presented drug content close to
their theoretical value (0.24 and 0.25 mg ml
-1), mean
1606 Nanoscale Res Lett (2010) 5:1603–1610
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pH, and negative zeta potential (between -26.0 and
-27.0 mV). Polydispersity indices below 0.20 indicated an
adequate homogeneity of these systems [26]. In addition,
neither the presence of rutin nor the presence of the poly-
mer inﬂuenced the physicochemical characteristics of
the structures. Moreover, nanocapsules and droplets of the
nanoemulsions were spherical in shape as showed by the
images obtained by transmission electron microscopy
(Fig. 1). Although the type of the nanostructured system
did not show any inﬂuence on the physicochemical char-
acteristics, the morphological analyses by TEM revealed
that rutin-loaded nanoemulsions (R-NE) presented rutin
nanocrystals around the droplets when compared to its
respective blank formulation (B-NE). Rutin nanocrystals
were not observed in nanocapsule formulation (R-NC).
These results can be explained by the leakage of rutin from
nanoemulsion due to the absence of the polymeric layer
around the droplets and its subsequent crystallization in the
aqueous dispersed medium as previously demonstrated for
dexamethasone under storage [37, 40].
Antioxidative Activity, UV Protodegradation,
and In Vitro Release Assay
Figure 2 shows the rutin photodegradation obtained for
both formulations (R-NC and R-NE), as well as for rutin
ethanolic solution (R-ES). The degradation proﬁles of rutin
in the nanostructured formulations (R-NC and R-NE) were
according to a ﬁrst kinetic order, and their respective
degradation constants were not signiﬁcantly different [k =
(6.1 ± 0.6) 10
-3 min
-1, k = (5.1 ± 0.4) 10
-3 min
-1,
respectively] (ANOVA, p[0.05). However, compared to
the rutin ethanolic solution [k = (35.0 ± 3.7) 10
-3 min
-1],
both nanostructured formulations showed a signiﬁcant
lower rutin degradation rate (ANOVA, p B 0.05). These
results showed that the association of rutin to the nano-
capsules or nanoemulsions led to an increase of 5.3 and 6.9
times in the rutin photostability, respectively, during the
30 min of exposure to UV radiation.
Table 2 Drug content, encapsulation efﬁciency, and pH of rutin-
loaded nanocapsules (R-NC) and rutin-loaded nanoemulsion (R-NE)
as well as their respective blank formulations (B-NC and B-NE)
(n = 3)
Formulation Drug content
(mg ml
-1)
Encapsulation
efﬁciency (%)
pH
B-NC – – 5.79 ± 0.03
R-NC 0.25 ± 0.01 93.33 ± 0.63 5.69 ± 0.08
B-NE – – 5.94 ± 0.10
R-NE 0.24 ± 0.01 93.83 ± 0.41 5.59 ± 0.01
– Not applicable
Table 3 Particle size, polydispersity index, and zeta potential of
rutin-loaded nanocapsules (R-NC) and rutin-loaded nanoemulsion
(R-NE) as well as their respective blank formulations (B-NC and
B-NE) (n = 3)
Formulation Particle size
(nm)
Polydispersity
index
Zeta potential
(mV)
B-NC 120.37 ± 2.44 0.11 ± 0.06 -20.55 ± 3.63
R-NC 124.30 ± 2.06 0.12 ± 0.02 -27.12 ± 9.19
B-NE 128.06 ± 3.38 0.13 ± 0.03 -26.03 ± 2.27
R-NE 124.17 ± 1.79 0.10 ± 0.02 -26.92 ± 1.45
Fig. 1 Transmission electron microscopy images of a B-NC,
b R-NC, c B-NE, and d R-NE. Bar 100 nm (200,0009)
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123The antioxidant activity (radical scavenging activity) of
rutin was evaluated by adding an amount of H2O2 in excess
to the samples (before the irradiation) leading to the
quantitatively controlled formation of  OH radicals, which
are the most harmful radicals formed under physiological
conditions. In this case, the decay kinetics were signiﬁ-
cantly different among all samples (R-NC, R-NE and
R-SE) and according to a ﬁrst-order kinetics (ANOVA,
p B 0.05). The nanoparticle formulations (R-NC and
R-NE) showed decay kinetics about 2.1 and 1.5 times
slower than the solution [k = (19.5 ± 0.5) 10
-3 min
-1,
k = (26.6 ± 2.6) 10
-3 min
-1 and k = (40.1 ± 1.7)
10
-3 min
-1, for R-NC, R-NE and R-SE, respectively],
indicating a prolonged antioxidant activity of rutin, when
associated to the nanostructures (Fig. 3). The difference
between the decay kinetics of the different nanoparticles
(ANOVA, p B 0.05) could be explained by the presence of
rutin nanocrystals adsorbed on the surface of the nano-
droplets of nanoemulsions (as observed by TEM—Fig. 1),
making rutin more readily accessible to react with the  OH
free radical.
In order to evaluate if the rutin release rate from the
different nanoparticles could also play an important role in
this different antioxidant behavior we carried out an in
vitro drug release experiment using the dialysis bag tech-
nique. Figure 4 shows the in vitro drug release proﬁles
from rutin-loaded nanocapsules (R-NC) and rutin-loaded
nanoemulsions (R-NE). Both formulations promoted a
rapid and similar release of rutin (release close to 100% in
24 h). The release proﬁles were modeled using the mono-
exponential and biexponential equations. According to the
values of the correlation coefﬁcients and the criterion for
model selection (MSC), the data ﬁt better to the biexpo-
nential equation (Table 4) for both formulations, showing a
burst release at an early stage followed by a sustained
phase.
The rate constants for the burst phase (k1) were
0.4113 ± 0.0765 h
-1 (R-NC) and 0.8164 ± 0.6039 h
-1
(R-NE) and for the sustained phase the rate constants (k2)
were 0.0310 ± 0.0163 (R-NC) and 0.1393 ± 0.1993 h
-1
(R-NE). For both phases, R-NC showed lower rate con-
stants compared to R-NE. The percentage of rutin related
the burst phase (a) for nanocapsules and nanoemulsions
was about 85 and 65%, respectively. On the other hand, the
percentage related to the sustained phase was about 13%
for R-NC and 32% for the R-NE. Such values showed that
rutin is about 60–80% adsorbed on the surface of nano-
structures [41, 42], suggesting that the radical scavenging
property of rutin against the  OH radical occurred mostly at
the interface particle/water. However, the inﬂuence of the
drug release from the inner compartment of the nanocar-
riers cannot be discarded, considering the slower drug
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Fig. 3 In vitro antioxidant activity of rutin-loaded nanostructures and
ethanolic solution after 30 min of UV irradiation
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Fig. 4 In vitro rutin release proﬁle from nanocarriers (R-NC and
R-NE) using the dialysis bag method (n = 3).The lines correspond to
the ﬁtting to the biexponential equation
Table 4 Rate constants, correlation coefﬁcients, and MSC obtained
by the mathematical modeling of drug release data from the different
nanocarriers (R-NC and R-NE)
R-NC R-NE
Monoexponential
k (h
-1) 0.3215 ± 0.0674 0.4336 ± 0.0242
r (range) 0.9979 ± 0.0010 0.9983 ± 0.0016
MSC (range) 2.9935 ± 0.2326 3.0585 ± 0.9828
Biexponential
k1 (h
-1) 0.4113 ± 0.0765 0.8164 ± 0.6039
k2 (h
-1) 0.0310 ± 0.0163 0.1393 ± 0.1993
a (mg ml
-1) 0.8447 ± 0.0597 0.6107 ± 0.3337
b (mg ml
-1) 0.1285 ± 0.0370 0.3201 ± 0.4125
r (range) 0.9997 ± 0.0002 0.9994 ± 0.0006
MSC (range) 6.5420 ± 0.5612 6.0185 ± 0.8945
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123release rate from R-NC at both release phases. This
hypothesis can be reinforced by the analysis of the release
half-life of rutin, calculated according to the biexponential
model. R-NC showed higher values (1.7 and 22 h for the
burst and sustained phase, respectively) compared to R-NE
(0.8 and 5 h for the burst and sustained phase, respec-
tively). This faster drug release from R-NE can be
explained by the absence of the polymer around the oily
droplets as well as by the presence of nanocrystals on their
surface, as observed by TEM.
Conclusions
This study showed for the ﬁrst time the development of
rutin-loaded nanocapsules and nanoemulsions, as aqueous
intermediate or ﬁnal systems to the development of nan-
omedicinescontainingrutin.Bothformulationspresentedan
increase in the rutin photostability and a prolonged in vitro
antioxidant activity, even if the main mechanism of asso-
ciation of rutin was the adsorption on the particle/droplet
surface, as determined by the mathematical modeling of
drugreleasedata.Moreover,thepresenceofpolymerdidnot
show any signiﬁcant inﬂuence in the increase of rutin
photostability. However, its presence in nanocapsules led to
a slower release rate and to a prolonged antioxidant activity
against the strongly reactive  OH radicals compared to the
rutin-loaded nanoemulsions. The results showed that such
nanostructured systems are a potential alternative to the
preparation of rutin delivery systems to treat different dis-
eases related to oxidative stress, including aging processes
caused by the action of free radicals.
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